

# TABLE OF CONTENTS

June 21, 2010

No. 2193

## REGULATORY

- 1 Mr Kan Stresses Need for Strong Economy, Strong Finance, and Strong Social Security
  - Regulations and Drug Industry Stimulation Should Be Reconciled: Mr Nagatsuma
  - Growth Strategy and Financial Reconstruction Are "Two Wheels of a Cart": Mr Naoshima
  - MEXT to Promote Science and Technology
- 10 NDA Review Period Drastically Shortened in FY2009: PMDA
- 10 ASCO, FDA Open "Expanded Access" Website on Use of Unapproved Drugs
- 11 Benefit-Sharing Based on CBD May Affect Pharma Industry
- 11 *Koroshō* Issues Memo to Clarify Requirements for Applicants
- 12 **REGULATORY NEWS IN BRIEF**
  - DSP Applies for Changes in Maximum Daily Dose for Meropen
  - Eribulin Receives Priority Review Status in the US
  - GL for Non-Clinical Evaluation of Anti-Malignant Tumor Agents Issued

## BUSINESS

- 3 Pfizer, Eisai Launch Lyrica
- 3 Bayer to Expand Packing Line for Chewable Tablets
- 4 Asahi Kasei's Pharm Sales to Fall below Target Set in Mid-Term Management Plan
- 4 Rezaltas No. 1 in Both HP, GP Market
- 6 **Commentary**
  - Mr Hasegawa Calls For Cooperation with Asian Countries
- 7 **BUSINESS NEWS IN BRIEF**
  - Eisai Licenses Netupitant + Palonosetron Combinations from Helsinn in US
  - Ranbaxy Launches Prasugrel in India

## GENERIC

- 7 **Survey**
  - High % of Prescriptions Still Prohibit Generic Substitution: Nihon Chouzai
- 8 Combined Sales of Top-4 Generic-Only Makers Up 15.5%
  - New Premium for Generics Dispensing Stimulating Use of Generics
- 8 JGA's Generics Information Supply System Gets on Track

## TOPICS

- 9 635 MSs to Take 1 Exam for Certification
- 12 Clinical Trial Costs Can Be Cut Using iPad: Mr Hasegawa

## SELF-MEDICATION

- 13 New OTC Drugs Consultation Services Started
- 13 *Koroshō* to Consult Medical Societies on 19 Switch OTC Drug Candidates

## R&D

- 14 Pfizer Oncology to Accelerate Multinational Trials to Eliminate "Drug Lag": VP S. Lowenthal
  - Aiming at Becoming the Leader in Lung Cancer Treatment
- 14 Roche Aims to Apply for 5 Anticancer Agents by 2013: VP Hal Barron
- 15 Merck Serono to Accelerate Development of Personalized Cancer Treatments: EVP V. Wein
- 15 **ASCO 2010 in Chicago (1)**
  - Eribulin Prolongs OS but Not PFS
  - Eribulin Shows High ORR in Japanese Patients
  - New c-Met Inhibitor Prolongs PFS in PII for NSCLC
  - T-DM1 + Pertuzumab Effective for HER2-Positive Breast Cancer
  - Roche's Hedgehog Inhibitor Safe in Combination with Standard Chemotherapy
  - Avastin Prolongs PFS, but Not OS in PIII in Stomach Cancer
  - Avastin Effective for HER2-Negative Breast Cancer in Japanese Patients
  - Erbitux + FOLFIRI Effective for Stomach Cancer in PII
- 18 **R&D NEWS IN BRIEF**
  - Eplerenone Meets Primary Endpoint Early in PIIIb: Pfizer
  - Lubiprostone Meets Primary Endpoint in PIII in Japan
  - Diovan Shows Hypotensive Effects in Elderly Japanese Patients
  - GenomIdea Receives Grant for Developing DNA Vaccines for Pandemic Flu

## MEDICAL FACILITIES & NURSING CARE

- 20 Risk of Stroke Reduced by Intensified Intervention in Japanese Diabetes Patients
- 20 Radiotherapy May Be Omitted in Elderly Breast Cancer Patients
- 22 ROCA Screening Useful for Early Detection of Ovarian Cancer
- 22 **Survey**
  - Over 60% of Local Gov't Hospitals Running at a Loss
- 23 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
  - Leptin Replacement Therapy for Lipotrophy Recommended as Advanced Therapy
  - Add Prevenar to Routine Vaccination Programs in Japan: Mr Kindler